Why Entera Bio Ltd.’s (ENTX) Stock Is Up 5.67%
As of Wednesday, November 18, Entera Bio Ltd.’s ENTX share price has surged by 5.67%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Cynthia McLaughlin
Tudor Pop
| Share Statistics | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $575.5 | $203.5 | 41% |
|
| Shares Out (Mil) | 145.1 | 55.2 | 69% |
|
| Institutional Ownership | 98.1% | 93.3% | 77% |
|
| Float (Mil) | 107.3 | 40.4 | 61% |
|
| Beta | 1.46 | 1.05 | 81% |
|
| Avg Daily Volume (000s) | 263 | 569 | 48% |
|
| Price Change (52-week) |
24.7% | 38.8% | 76% |
|
| Growth | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (0.4%) | (10.7%) | 40% |
|
| EPS (5yr) | 16.4% | 15.4% | 61 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 19.0% | (15.7%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($29) | ($44) | 20% |
|
| EPS (TTM) | ($0.405) | ($1.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($35) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $257 | $142 | 29% |
|
| Valuation | ENTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.09 | 1.96 | 60% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (20.0%) | (47.0%) | 20% |
|
| ROE | (20.3%) | (51.8%) | 23% |
|
| Liabilities to Assets | 1.0% | 29.6% | 0% |
|
| F-Score | 3 | 3 | 18% |
|
Entera Bio Ltd. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors